National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 5) (Cth)
PB 69 of 2022
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 5)
National Health Act 1953
___________________________________________________________________________
I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 98C(1) of the National Health Act 1953.
Dated 28 July 2022
NIKOLAI TSYGANOV
Assistant Secretary (Acting)
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Contents
1.......... Name............................................................................................................................................ 1
2.......... Commencement............................................................................................................................ 1
3.......... Authority...................................................................................................................................... 1
4.......... Schedules..................................................................................................................................... 1
Schedule 1—Amendments 2
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019
Name
(1)This Instrument is the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 5).
(2)This Instrument may also be cited as PB 69 of 2022.
Commencement
(1)Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
| Commencement information | ||
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 August 2022 | 1 August 2022 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2)Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
Authority
This instrument is made under subsection 98C(1) of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)
Schedule 3, entry for Hydromorphone
omit: Oral solution containing hydromorphone hydrochloride 1 mg per mL, 473 mL substitute: Oral solution containing hydromorphone hydrochloride 1 mg per mL, 1 mL
Schedule 4, entry for Calcipotriol with betamethasone
omit:
| Calcipotriol with betamethasone | Gel containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g |
Schedule 4, after entry for Nicorandil in the form Tablets 20 mg, 60
insert:
| Nirmatrelvir and ritonavir | Pack containing 4 tablets nirmatrelvir 150 mg and 2 tablets ritonavir 100 mg, 5 |
0
0
0